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Abstract Chemotherapies feature a low success rate of
about 25%, and therefore, the choice of the most effective
cytostatic drug for the individual patient and monitoring the
efficiency of an ongoing chemotherapy are important steps
towards personalized therapy. Thereby, an objective method
able to differentiate between treated and untreated cancer
cells would be essential. In this study, we provide molecular
insights into Docetaxel-induced effects in MCF-7 cells, as a
model system for adenocarcinoma, by means of Raman
microspectroscopy combined with powerful chemometric
methods. The analysis of the Raman data is divided into
two steps. In the first part, the morphology of cell organ-
elles, e.g. the cell nucleus has been visualized by analysing
the Raman spectra with k-means cluster analysis and arti-
ficial neural networks and compared to the histopathologic
gold standard method hematoxylin and eosin staining. This
comparison showed that Raman microscopy is capable of
displaying the cell morphology; however, this is in contrast
to hematoxylin and eosin staining label free and can there-
fore be applied potentially in vivo. Because Docetaxel is a
drug acting within the cell nucleus, Raman spectra origi-
nating from the cell nucleus region were further investi-
gated in a next step. Thereby we were able to differentiate
treated from untreated MCF-7 cells and to quantify the
cell–drug response by utilizing linear discriminant analysis
models.
Keywords Raman microspectroscopy.Docetaxel.Breast
cancer.MCF-7
Introduction
Breast cancer is the most common cause of death of women
worldwide [1]. Due to the low effectiveness of chemother-
apeutic agents of about 25% as one possible origin of the
high mortality rates [2], it is of utmost importance to achieve
a comprehensive understanding about the therapeutic mech-
anism of cytostatics in order to improve chemotherapy. In
addition, monitoring the efficiency of an ongoing chemo-
therapy and supporting the choice of the most effective
cytostatic drug would be an important step towards person-
alized therapy.
This document is a collaborative effort of Melanie Becker-Putsche and
Katharina Hartmann and they contributed equally to the presented
work.
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apeutic drugs for patients is based on clinical trials and
observations made on the courses of a disease for other
patients. This practice harbours the risk that the individual-
ity of patients is disregarded. Also the selection of drug
combinations is widely empirical and often done by trial
and error. However, since the introduction of chemothera-
peutic agents investigations deal with an optimization of the
drug selection for the individual patient. Especially in vitro
chemosensitivity tests to predict a chemotherapy response
gain impact, e.g. 3-(4,5-dimethyl-thiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT), membrane and ATP
assays and genomic analyses [3–5]. Nevertheless, some
assays turned out to be insufficient of directing therapy [5]
and the above mentioned techniques are not widely used in
clinical practice.
During the last decades Docetaxel (DCT, Taxotere®)
became a widely used chemotherapeutic agent [6] against
prostate, lung, stomach and ovarian cancer. It is known as
highly active anticancer drug and one of the most effective
medication against breast carcinoma [7]. DCT is a semi-
synthetic taxane, which is produced by the esterification of
10-deacetyl baccatin III, an extract from needles of the
European yew (Taxus baccata L.) [8].
DCT has an enoumerous affinity to the β-tubulin of the
microtubules of the cytoskeleton. Commonly there is an
equilibrium between polymerisation and depolymerisation
of the microtubles. This dynamic reorganisation is import
for several cellular processes, e.g. the uptake, transport and
secretion of vesicles, cell movements, formation of the cell
shape and segregation of the chromosomes during mitosis
[9]. A DCT treatment disturbs the depolymerisation of the
microtubles causing a cell-cycle arrest [9–11]. Thereby, an
ongoing controversy about the exact mode of action and the
death mechanism exists: Morse et al. determined the non-
apoptotic mitotic catastrophe with its missegregation of the
chromosomes during mitosis and resulting micronuclei as
the primary death mechanism of DCT treated human breast
cancer cells, e.g. MCF-7 [9]. In contrast several other con-
tributions report about apoptosis as the main mechanism of
cell death after a DCT treatment induced mitotic catastrophe
[12–15]. In this controversy, it should be also considered,
that the response of antimicrotuble drugs might cause a
dose- and cell line-specific mixtures between apoptotic and
mitotic cell death, depending on the genetic background [9,
10, 16].
Raman spectroscopy in combination with optical micros-
copy has established itself because of its non-invasive char-
acter, high molecular specificity, minimal sample
preparation and high spatial resolution in the micrometer
range to an extremely powerful analytical method. Thereby
Raman microscopy has been recognized within the last
years to be a very capable method to analyse biological
samples like, e.g. eukaryotes [17–21] as well as prokaryotes
[22–28] and even viruses [29]. By doing so, it allows
answering a broad range of biomedical questions like, e.g.
early diagnosis of cancer [30–36]. Because of the subtle
biological differences involved, this requires a multivariate
treatment of Raman spectra in order to extract all necessary
bio-chemical information [37].
In comparison to Fourier transform infrared spectrosco-
py, which is also capable to acquire structural information of
cell organelles [38], Raman microspectroscopy provides the
unique capability to observe biochemical information from
living cells [39–41]. Thereby, the non-disturbing low
Raman-scattering cross section of water is of crucial impor-
tance. It allows the investigation of living cells in buffer
solution or in their culture media.
Furthermore, several publications deal with the effects of
chemotherapeutic agents on cells: In 1982, Manfait et al.
already investigated the interaction of the anthracycline
Adriamycin with human DNA via Raman and resonance
Raman spectroscopy and found that the chromophores of
Adriamycin intercalate into the GC sequences of the DNA
and that hydrogen bonds are formed [42]. In recent years,
many experiments cover the biochemical and spectral
changes in Raman spectra of cells undergoing apoptosis
due to a treatment with chemotherapeutic drugs. Especially
the investigation of living cells gains impact [39–41]. There-
by, Raman spectra from the same living cells at different
intervals were detected. Zoladek et al. even presented an
experimental setup, which allows the maintenance of the
cells under sterile physiological conditions during Raman
measurements [40]. Currently, the optimization of the ex-
perimental design is of interest. Laser tweezers were applied
to both optical trapping of single suspensions cells and
simultaneous Raman spectroscopy [43] as well as single-
cell patterned microarrays [39]. In addition, modern techni-
ques like resonance Raman and surface enhanced resonance
Raman scattering [44] and surface enhanced Raman scatter-
ing (SERS) [45] were utilized to monitor the effects intro-
duced by chemotherapeutic agents on cancer cells. Hence,
SERS has shown its potential as a simple and sensitive drug
screening tool potentially even in vivo.
The aim of the current study is to investigate the interac-
tion between DCT and the cultivated human breast adeno-
carcinoma cell line MCF-7 by Raman microspectroscopy in
combination with special statistical/chemometrical methods.
The resulting Raman images will be validated by the histo-
pathological gold standard hematoxylin and eosin staining.
Furthermore the additionally information in the Raman
scans should be used for determining the function of DCT
on MCF-7 cells in a quantitative and objective manner. The
successful realization of these goals would be a significant
step towards a personalized medicine applying Raman
microspectroscopy as control tool.
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Cell line selection and cell cultivation
The breast cancer cell line MCF-7 (Michigan Cancer
Foundation-7), established by Soule et al. in 1973, contains
isolatedepithelialcells froma pleural effusionfroma 69years
old caucasian female patient with metastatic mammary carci-
noma [46]. Cells were cultivated in cell culture flasks with
Roswell Park Memorial Institute 1640 medium supplemented
with 10% fetal bovine serum and 1% penicillin/streptomycin.
Cultures were maintained at 37 °C in a humified atmosphere
of 5% CO2. For the experiments, cells were harvested by
trypsinization, centrifugation and finally re-cultured on fused
silica slides (Frank Optic Products GmbH, Germany) in petri
dishes with the same cultivation conditions for further 24 h.
Cell treatment with DCT
DCT powder was resolved in ethanol and diluted by the
growth media. Thereby, the used DCT solution contains an
ethanol content of only 0.1% to prevent chemical alterations
in MCF-7 cells.
MCF-7 cells were exposed to the growth medium supple-
mented with various DCT concentrations. Table 1 gives an
overviewof the applied concentrations and exposuretimes. In
the first test series, slides with grown cells were treated with
10and100nMDCTconcentrationfor24h(Batch1)and48h
(Batch 2), respectively. The cells of Batch 3 were incubated
for24hwithDCT.SubsequentlytheDCTcontainingmedium
was replaced with a normal medium (without DCT). A cell
cultivationstepoffurther24hfollowed.Thesecondtestseries
(Batch 4) contained MCF-7 cells treated for 48 h with DCT
concentrations of 2.5, 5 and 7.5 nmol/l. Cultures of untreated
cells were used as references. Each test series (batch) was
prepared twice. For Raman data acquisition, the cells were air
dried and stored at room temperature. For each batch, 2 to 6
cells were measured, while approximately 20,000 Raman
spectra were recorded.
Hematoxylin and eosin staining
Hematoxylin and eosin (H&E) staining was used as common
histopathological analysis for comparison with the Raman data.
H&E staining allows the assignment of various structures in
tissues and single cells [47]. Hematoxylin stains all basophilic
components blue, especially the nucleus containing DNA and
RNA, and the rough endoplasmatic reticulum with an accumu-
lation of ribosomes as a result of a coordination bond between
aluminum and phosphor atoms of the DNA and RNA [48].
Eosin stains the cytoplasm, connective tissue and collagen
fibers (eosinophilic substances) red due to ionic bonds between
the anionic dye and cationic plasma proteins. The samples were
stained according to a well established standard protocol [49].
Raman microspectroscopy
Ramanmeasurementswereperformed withthe confocalRaman
microscope [50] CRM 300 (WITec, Germany) equipped with a
50×/NA 0.95 objective (Zeiss, Germany). As excitation light,
the 785 nm output of a diode laser was used with a power of
50 mWat the sample. For each spectrum, an acquisition time of
10 s was applied. The back scattered light was spectrally dis-
persed with a monochromator of 300 nm focus length equipped
with a 600 lines/mm grating and detected by an EM-CCD
camera with pixels operated at −75 °C. The cell Raman maps
were recorded with a step size of 0.5 μm.
Chemometric evaluation
The large amount of Raman data was evaluated applying
chemometric methods. The calculations were performed on
a commercially available PC system (Intel(R) Core(TM)
2Duo CPU, E67502.66 GHz, 1.97 GB RAM). The compu-
tations were done in R [51], a statistical language. All
Raman spectra were preprocessed as described in a previous
publication [32], while here only a brief overview is given.
First a wavenumber calibration employing the commonly
usedwavenumberstandard4-acetamidophenolwasperformed.
For the chemometric analysis, the Raman spectra were truncat-
ed to the wavenumber region between 600 and 1,800 cm
−1
(part of the fingerprint region). Afterwards, a background
Table 1 Overview of applied DCT treatments
Batch Slide
number
Exposure
time (h)
DCT concentration
(nmol/l)
First test series
1 T01 24 0
T02 10
T03 100
2 T04 48 0
T05 10
T06 100
3 T07 24+24 0
T08 10
T09 100
Second test series
4 T10 48 0
T11 2.5
T11 5
T11 7.5
T12 10
T13 100
A study of Docetaxel-induced effects in MCF-7 cells 747subtraction was performed applying a 5th order polynomial
[52] to correct for the fluorescence background followed by a
vector normalization. Prior to the analysis, a dimension reduc-
tion to 50 PCA scores was carried out to reduce the dimension
of the data matrix without losing too much information. The
chemometric analysis includes k-means cluster analysis [53],
artificial neural networks (ANN) [32] and linear discriminant
analysis (LDA) models [54]. While the k-means cluster analy-
sis and the ANN were used for visualization, the LDA model
was applied as a classification technique. The LDAwas cross-
validated by a leave-one-out-cross-validation (LOO-CV) [55].
Results and discussion
Visualization of the cell morphology—qualitative analysis
DCT induces nucleus fragmentation due to apoptosis or
mitotic catastrophe at the beginning of the effect chain
[9–11, 16]. For that reason, the first aim was the visualiza-
tion of the morphology of MCF-7 cells. This will be an
important step for further analyses, e.g. for the realization of
a quantitative analysis presented in the “Determining the
cell–drug response—quantitative analysis” section. In order
to visualize the cell morphology, we applied an ANN to
analyse the Raman xy-scans of whole single cells. The ANN
analysis yields the DNA/RNA distribution for each mea-
sured Raman spectrum allowing the creation of a Raman
image displaying the DNA/RNA content of the whole cell.
These DNA/RNA Raman maps can be validated by com-
paring them with the histopathologic gold standard H&E
staining. This validation of the applied ANN algorithm
showed that DNA/RNA Raman maps display the position
and shape of the cell nucleus.
Figure 1 compares the DNA/RNA distribution generated
by an ANN with a subsequently stained H&E image of the
same non DCT treated cell. In the Raman image, high DNA/
RNA concentrations are displayed in red, while low concen-
trations appear blue. It can be clearly seen that the position,
shape and size of the nucleus are comparable in both images.
Furthermore, the lower left region of the cell (see encircled
regioninFig.1) showsonefurtherstructurebothvisible inthe
H&EaswellasintheimagegeneratedbyanANN.Theorigin
of this cannot be definitely clarified, but one possibility could
be the presence of extra nuclear RNA, e.g. rough endoplas-
matic reticulum or messenger, transfer or ribosomal RNA.
ThisassumptionwasconfirmedbyFigureS1intheElectronic
Supplementary Material displaying Raman spectra from the
nucleus and cytoplasm. The Raman spectra of cytoplasm and
the nucleus show a significant Raman band at 811 cm
−1
assigned to the vibration of the sugar-phosphate backbone of
the RNA [56]. Therefore, the presence of extra nuclear RNA
isprobableinthe nucleus aswell as inthe cytoplasm.Overall,
Raman microspectroscopy providessimilarinformation asthe
histological gold standard H&E staining. The great advantage
is that Raman microspectroscopy is label free and therefore
potentiallycapable for invivoapplications in comparisonwith
the H&E stain. This proof-of-principle is necessary for further
experiments dealing with the effect of docetaxel on living
cancer cells over a longer period of time. To investigate such
dynamic cellular events, a measurement technique requiring a
label is not suitable. Raman microspectroscopy is label free
and non-invasive and thus, cellular functions remain un-
touched in living cells during the measurement. Overall, the
usedANNalgorithmisideallysuitedtoidentifyRamannuclei
spectra, which can be further analysed (see the “Determining
the cell–drug response—quantitative analysis” section).
In the following the ANN Raman images will be ana-
lysed with respect to identify structural differences in treated
and untreated MCF-7 cells. Figure 2 (first row) depicts the
Raman images of the DNA/RNA content of MCF-7 cells
treated with 0, 10 and 100 nmol/l DCT for 48 h. In addition,
Fig. 1 Comparison of a MCF-7
cell stained with H&E (left) and
the chemical map of the DNA/
RNA distribution based on
Raman spectroscopic data
(right). The circle marks a
structure in the cell with further
DNA or RNA content outside
the nucleus
748 K. Hartmann et al.k-means cluster analyses were carried out to visualize cell
compartments, mainly the nucleus region (Fig. 2, second
row). Both chemometrical methods (ANN and k-means
cluster analysis) generated the same result: untreated
(0 nmol/l) MCF-7 cells show compact cell nuclei, while the
cells treated with 10 nmol/l as well as with 100 nmol/l
DCT for 48 h exhibit fragmented nuclei. These pronounced
differences between treated and untreated cells were con-
firmed by subsequent H&E staining of the same samples
(Fig. 2, third row).
Moreover, DCT induced effects on the cell morphology
become visible in almost all measured MCF-7 cells. Some
examples are shown in Figure S2 in the Electronic Supple-
mentary Material. The Raman images illustrate once more
an ANN calculation displaying the DNA/RNA content.
These cells were treated with 100 nmol/l DCT for the three
different exposure times of 24 h, 48 h and 24+24 h (see
Table 1). It can be clearly seen that almost all MCF-7 Raman
images are characterized by fragmented nuclei. An excep-
tion from this behavior can be found for cell 2C showing a
homogeneous cell nucleus, which might be attributed to the
fact that DCT is only effecting cells during mitosis. Since
the cell cycle was not synchronized, it is possible that the
cell 2C was not in a mitotic stage. Furthermore, the individ-
ual behavior of a cell should be also considered.
However, these results point out that Raman microspec-
troscopy combined with chemometrical analysis has a great
potential to image chemical changes in cells. The used ANN
Fig. 2 Raman images of whole single cells generated by ANN analysis
showing the DNA/RNA distribution of untreated (0 nmol/l) and DCT
treated (10 nmol/l, 48 h and 100 nmol/l, 48 h) MCF-7 cells. Dark red
regions mark high DNA/RNA concentrations and thereby the nucleus
position (1st row); results of the k-means cluster analysis (2nd row)a n d
corresponding H&E images of the same cells (3rd row)
A study of Docetaxel-induced effects in MCF-7 cells 749algorithm is an optimal method to visualize the cell nuclei
and thereby identify Raman nuclei spectra. The identifica-
tion of nuclei spectra is an important step result for the
subsequent quantitative analysis of the cell–drug response
for DCT treated and untreated MCF-7 cells.
Determining the cell–drug response—quantitative analysis
It is of utmost importance to improve and personalize che-
motherapy. Thereby the appropriate choice of the most
effective chemotherapeutic drug for the individual patient
and the possibility of an online monitoring of the progress of
the chemotherapy are two of the major challenges towards
increasing the effectiveness of cytostatic drugs and towards
a personalized treatment. Raman microspectroscopy in com-
bination with chemometrical methods has the potential to
significantly contribute to tackle these challenges. Raman
images in contrast to H&E images are of multivariate nature
that is they contain additional spectral information which
can be used to differentiate between untreated and treated
MCF-7 cells or to unravel the (spectral) cell–drug response.
In order to differentiate between untreated and DCT
treated MCF-7 cells, a LDA was utilized to classify the
nucleus Raman spectra of treated and untreated cells. The
resulting classification model was evaluated by a LOO-CV
and the confusion matrix is given in Table 2. The LDA
model classified 10,176 out of 10,253 cell nucleus Raman
spectra of treated cells and 8,294 out of 8,356 cell nucleus
Raman spectra from untreated cells correctly, which corre-
sponds to an accuracy of 99.2%. This accurcy rate together
with the achieved sensitivity and specificity of also 99.2%
shows that Raman microspectroscopy is perfectly suited to
differentiate between treated and untreated MCF-7 cells.
Figure 3 displays the mean Raman spectra of the two classes
of the LDA model that is DCT treated (red) and untreated
(black) MCF-7 cells together with the corresponding LD
scaling vector. The LD scaling vector (green) indicates the
spectral differences within the Raman spectra allowing for
the clear separation between treated and untreated cells. A
comparison between the mean Raman spectra of treated and
untreated MCF-7 cells show that the intensity of the band at
785 cm
−1 which can be assigned to a DNA/RNA vibration
(OPO stretch DNA/RNA) [56, 57] is increased in the mean
Raman spectrum of DCT treated cells as compared to un-
treated cells. The reason for this increasing 785 cm
−1 band
intensity could be a local DNA concentration enhancement
due to the nucleus fragmentation and the corresponding
Table 2 Confidence table of the LDA model for separation of control
data vs. Raman data containing cell–drug interactions
Predicted labels True labels
Raman
spectra
of treated cells
Raman spectra
of untreated
cells
Raman spectra of treated cells 10176 62
Raman spectra of untreated cells 77 8294
Fig. 3 Raman mean spectra of
DCT treated (red spectrum) and
untreated (black spectrum)
MCF-7 cells. Significant differ-
ences are visible, e.g. the DNA/
RNA peak at 785 cm
−1 and
amide I peak at 1,658 cm
−1.
These regions are confirmed by
the LD scaling vector (green
spectrum)
750 K. Hartmann et al.increased DNA condensation. Furthermore the amide I vi-
bration at 1,658 cm
−1 [56, 57] is decreased in intensity in the
mean Raman spectrum of treated MCF-7 cells as compared
to the spectrum of untreated cells, which might be also a
consequence of the nucleus fragmentation and the
corresponding degradation of the protein structures in the
nucleus.
In order to investigate DCT concentration dependent cell-
response Raman spectra recorded for cells treated with 2.5, 5,
7.5, 10, and 100 nmol/l DCT for 48 h were analysed (see
Table 1). It should be noted that only the Raman spectra
originating from the cell nucleus were considered. A LDA
model was used to calculate the spectral differences between
the five different concentrations. The LDA model was trained
with two training sets including Raman spectra of cells ex-
posed toDCTconcentrations of2.5 and 100 nmol/lfor 48h to
achieve the corresponding LD scaling vector. As test sets,
Raman spectra of cells treated with 5, 7.5, and 10 nmol/
l DCT were projected on this LD scaling vector. Figure 4A
gives an overview of the drug concentration dependent class
affinities. Here, the distribution of the scalar product of each
Raman spectrum with the calculated LD vector is shown (LD
value). Overall, the LDA analysis reveals that the highest cell
response occurs after a treatment with DCT concentrations
between 7.5 and 10 nmol/l showing that the lowest concen-
tration that is detection limit where the influence of DCT on
the MCF-7 Raman spectra is still visible lies at a DCT con-
centration of 7.5 nmol/l. In Fig. 4B, the LD value (e.g. the
inner product of every spectrum with the LDA value) is
plotted against the drug concentration on a logarithmic scale.
This LD value can be interpreted as the cell response. The
points in Fig. 4B result from the maxima of the histogram in
Fig. 4A for every DCTconcentration. The arrangement of the
values suggests a sigmoidal trend, which confirms studies
about the dose-effect relationship by Jodrell et al. [58]a n d
Jakobsen et al. [59]. These findings indicate, that even low
DCTconcentrations of 7.5 nmol/l induce chemical alterations
in MCF-7 cells.
Fig. 4 (A)LDAclassificationofRamandataofvariousDCTtreatments.
The histogram of the LD value (scalar product) of all five DCT concen-
trations is given. With the lowest and highest concentration, the LDA
model was trained and all spectra were projected on the LDA model. (B)
The dose–effect relationship, as a function of the logarithmically DCT
concentration, is visualized. The LD-value can be interpreted as cell
response for DCT treatment and shows a sigmoidal trend, which can be
utilized for determining the spectral detection limit
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We investigated DCT induced effects on a breast cancer
model system (MCF-7) by means of Raman microspectro-
scopy in combination with powerful chemometrical meth-
ods. DCT induces nucleus fragmentation at the beginning of
the effect chain. Therefore, we visualized the morphology of
cell organelles, e.g. the cell nucleus by applying k-means
cluster analysis and an ANN. The ANN generated images
are highly correlating with the DNA/RNA content. The in
that way generated Raman images highlighted DCT induced
morphological alterations in the nuclei structure, caused by
the drug induced depolymerisation of microtubules during
mitosis. These images based on Raman spectra were vali-
dated with the histopathologic gold standard method, the
H&E staining. Overall, both Raman imaging analysing
methods (k-means clustering and ANN) were capable of
visualization the cell morphology.
By using a LDA with the preselected nuclei spectra, it
was possible to differentiate between treated and untreated
MCF-7 cells with an accuracy of 99.2%. Thereby, Raman
mean spectra of DCT treated and untreated cells show
significant differences at 785 cm
−1, which can be assigned
to a DNA/RNA vibration, and the amide I peak at
1,658 cm
−1 due to the DCT induced fragmentation of the
nuclei. DCT treatments with concentrations lower than
10 nmol/l (2.5, 5 and 7.5 nmol/l) were implemented addi-
tionally to achieve quantitative results about the efficiency
of DCT by applying a LDA analysis. A drug concentration
of 7.5 nM was indicated as the detection limit of monitoring
spectral changes in Raman spectra of treated MCF-7 cells.
In the present contribution, it was shown that the analysis
of cellular Raman spectra by means of modern chemometric
approaches is capable of monitoring the impact of cytostatic
agents. The effect of a drug on the cell morphology can be
visualized and the spectral differences between treated and
untreated cells can be calculated. With the help of the
visualization and detection of the effect of chemotherapeutic
drugs it could be possible to monitor the ongoing chemo-
therapy. This could be achieved by applying the presented
methodology on real patient cell samples. In that way, the
process and the benefit of an ongoing chemotherapy would
be determined in an objective manner. Therefore an individ-
ualized medicine with Raman spectroscopy as control tool
seems reasonable. The above presented results can be used
in another way. If quantum mechanical calculations (based
on DFTcalculations or in the Hartree–Fock regime) [60, 61]
of DCT, microtubules and the respective motor proteins are
carried out, a deeper understanding of the work mechanism
of DCT can be obtained. This workflow is outlined in [62,
63]. Nevertheless, the quantum mechanical calculations
have to be optimized for the application to huge proteins
and cell structures. This is an emerging field, which in
combination with experimental data, like presented above,
would enhance our understanding of the bio-chemical pro-
cesses inside of cells and the their interaction with drugs.
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